Microbiotica to present at key industry conferences in Q3 2022

Cambridge, UK, 20 June 2022 – Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, confirms its upcoming scientific conference attendance.

Microbiome Movement – Drug Development, 21-24 June 2022, Boston, US
Dr Ron Carter, Microbiotica’s CMO, will be contributing to a panel at Microbiome Movement – Drug Development, taking place in Boston, US, from 21 to 24 June. This is a key conference series for the microbiome industry, and will focus on taking a collaborative approach to close the clinical gap, discover the next generation of microbiome-based therapeutics and establish new partnerships to accelerate research.

Ron will contribute to a panel discussion entitled “Learn How to Advance Your Clinical Trial Recruitment and Progress Your Pipeline” on 22 June at 12:00 pm local time, along with speakers from Enterobiotix, Series Therapeutics, Gusto Global and Alveolus Bio.

Microbiome Connect Europe, 6-7 July 2022 – Amsterdam
Microbiotica’s Director, Cell Biology, Dr Ghaith Bakdash will be presenting on the topic of “MB097: A clinically defined consortium of bacteria with potent anti-tumour activity” at the 8th Annual Microbiome Connect: Europe 2022 conference. This conference highlights the most advanced drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.

Ghaith’s talk is scheduled for 9.30am local time on 7 July.

Anaerobe 2022, 28-31 July – Seattle, US
Microbiotica’s Director, Discovery Microbiology, Dr Anne Neville will be presenting at Anaerobe 2022 which takes place in Seattle from 28 to 31 July on the subject of “Anaerobic Cultivation and Strain-Banking from the Human Gastrointestinal Tract”. This conference will address both the clinical and microbiological aspects of anaerobes, as related to human diseases, animal diseases, and environmental conditions.

Anne’s talk will be at 1.45pm local time on 30 July.

Immuno UK, 29-30 September – London, UK
Microbiotica’s VP Transitional Biology, Dr Mat Robinson, will be discussing “Co-Therapy Development For Immuno-Oncology” at Immuno UK, an event focussed on the design and delivery of innovative immunotherapies to transform cancer care, on 29 September at 2.20pm local time.

-ENDS-

Contact

Microbiotica
Ro Gardner
T: +44 1223 869302 / M: +44 7801 480569
E: rgardner@microbiotica.com

Microbiotica (Media relations)
Melanie Toyne-Sewell / Agnes Stephens / Batoul Ali
T: +44 20 7457 2020
E: microbiotica@instinctif.com

NOTES TO EDITORS

About Microbiotica

Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.

Consisting of the leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD and it has established major clinical and academic partnerships in these areas.

Spun out of the Sanger Institute in 2016, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners, and Tencent.

For more information, please visit www.microbiotica.com, LinkedIn and Twitter.